Trust Signals
Written by the FormBlends Medical Team. Reviewed against primary literature on PubMed and the FDA prescribing information for tesamorelin (Egrifta SV, Theratechnologies). No author holds a financial interest in either compound. All claims are graded by evidence tier. This page does not constitute medical advice.
Key Takeaways
- Tesamorelin is FDA-approved for HIV-associated lipodystrophy based on two Phase 3 RCTs each enrolling more than 400 participants; hexarelin has no approved indication in any jurisdiction.
- Hexarelin acts on the ghrelin receptor (GHSR-1a) and a separate CD36-related pathway; tesamorelin acts exclusively on the GHRH receptor. The different receptor profiles explain divergent side-effect signatures, especially hexarelin's transient cortisol and prolactin elevations.
- Hexarelin undergoes faster GHSR-1a desensitization than tesamorelin does at its receptor, making continuous use problematic within weeks.
- In the tesamorelin Phase 3 program, visceral adipose tissue (VAT) reduction averaged roughly 15 to 18 percent versus placebo at 26 weeks in HIV-positive participants. No comparable long-duration body-composition RCT exists for hexarelin in humans.
- Both peptides degrade rapidly in solution at room temperature; tesamorelin's approved pharmaceutical product has defined label stability, while research-grade versions of either compound carry no guaranteed purity or shelf life.
Direct Answer: Which Is Better, Hexarelin or Tesamorelin?
Table of Contents
- What are hexarelin and tesamorelin, and how do they work?
- Evidence ledger: what does the research actually show?
- Mechanism with numbers: receptor pharmacology and GH kinetics
- What most pages get wrong about these two peptides
- Side-effect profiles: what the trials and pharmacology studies document
- Honest head-to-head comparison table
- Chemistry behind the rules: why storage and stability matter more than you think
- Operational and label literacy: how to evaluate what you are buying
- Desensitization and cycling: what the data say
- FAQ
- Sources
What Are Hexarelin and Tesamorelin, and How Do They Work?
Hexarelin is a synthetic hexapeptide (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) developed in the 1990s as a potent growth hormone releasing peptide (GHRP). It mimics ghrelin's effect on the pituitary by binding GHSR-1a, causing strong but short-duration GH pulses. It also interacts with a distinct scavenger receptor pathway (CD36/SRB-1), which is responsible for some of its non-GH cardiovascular observations.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Tesamorelin is a synthetic analogue of endogenous GHRH, consisting of the full 44-amino-acid GHRH(1-44) sequence with a trans-3-hexenoic acid group added to the N-terminus. This modification extends its plasma half-life compared to native GHRH (roughly 30 to 40 minutes versus less than 7 minutes for native GHRH in published pharmacokinetic work) while preserving receptor selectivity. It acts exclusively on the pituitary GHRH receptor, stimulating pulsatile GH release in a manner that preserves more physiological feedback regulation than direct GH injection.
Evidence Ledger: What Does the Research Actually Show?
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Tesamorelin reduces VAT in HIV-associated lipodystrophy | Two Phase 3 RCTs (N greater than 400 each; Falutz et al., NEJM 2010 and the LIPO series) | Positive (roughly 15 to 18% VAT reduction vs placebo at 26 weeks) | High |
| Tesamorelin raises IGF-1 levels in treated adults | Phase 3 RCT data and pharmacodynamic studies | Positive (IGF-1 increases documented in trial populations) | High |
| Hexarelin acutely stimulates GH release in humans | Small controlled pharmacology studies (mostly N less than 30) | Positive (dose-dependent GH elevation confirmed) | Moderate |
| Hexarelin transiently elevates cortisol and prolactin in humans | Small human pharmacology studies | Positive (transient elevations documented acutely) | Moderate |
| Hexarelin improves body composition over weeks to months | Animal studies; no human multi-month RCT identified | Positive in rodents; unknown in humans | Very Low |
| Hexarelin has direct cardioprotective effects in humans | Animal models; one small human study in GH-deficient patients | Mechanistically plausible; not established clinically | Low |
| Tesamorelin reduces VAT in non-HIV adults with obesity | Small investigational studies; no Phase 3 RCT in this population | Directionally positive; not regulatory-quality evidence | Low |
| Long-term tesamorelin use preserves VAT reduction after discontinuation | Phase 3 extension data showing VAT returns toward baseline after stopping | Negative: benefit is not sustained off-drug | High |
Mechanism with Numbers: Receptor Pharmacology and GH Kinetics
Hexarelin binds GHSR-1a with high affinity. Published in vitro data place its potency in the low nanomolar range. A single subcutaneous dose of hexarelin in the range of 1 to 2 mcg/kg produces measurable peak GH elevations within 15 to 30 minutes in human subjects, with return to baseline by approximately 90 to 120 minutes in published pharmacology studies. This does NOT prove that transient GH spikes produce the body composition changes sometimes attributed to hexarelin; GH secretion and tissue remodeling are separated by complex IGF-1 mediated downstream events.
Tesamorelin's N-terminal modification extends its plasma half-life to roughly 30 to 40 minutes, as documented in its original pharmacokinetic characterization. Native GHRH has a plasma half-life of under 7 minutes in most reported human studies. A daily subcutaneous dose of 2 mg (the approved dose in Egrifta SV) produces a measurable increase in mean 24-hour GH concentrations while maintaining some pulsatility, which is mechanistically preferable to supraphysiological flat elevation because it reduces IGF-1 overshoot risk compared to direct GH injection.
Crucially: elevated IGF-1 is a plausible mechanism for VAT reduction, but IGF-1 elevation is also the mechanism for most of tesamorelin's serious risks, including potential promotion of existing malignancy. The same IGF-1 rise that may explain efficacy explains the contraindication in active cancer patients.
What Most Pages Get Wrong About These Two Peptides
The receptor conflation error. Nearly every comparison page treats hexarelin and tesamorelin as two versions of the same thing, "GH boosters," and ranks them on potency alone. They act on entirely different receptors and have different downstream pharmacology. Hexarelin's GHSR-1a activation also stimulates appetite and has neuroendocrine effects (cortisol, prolactin) that tesamorelin does not share. These are not interchangeable compounds.
The desensitization problem is consistently understated for hexarelin. Most peptide blogs mention cycling without explaining why it is mandatory. GHSR-1a downregulates with repeated stimulation. Human and animal data show that the GH response to hexarelin blunts substantially with continuous use over days to weeks. Tesamorelin, acting through the GHRH receptor, shows a less pronounced acute desensitization in the pituitary setting, and its Phase 3 trial maintained efficacy over 26 weeks of daily dosing.
Research-grade purity is not pharmaceutical-grade purity. Egrifta SV is manufactured under GMP with lot-release testing. Research-grade hexarelin or tesamorelin from peptide suppliers is not. Independent mass spectrometry testing of research peptide products has found substantial variation in actual peptide content and presence of truncated or oxidized byproducts. This is not a minor footnote; it affects every efficacy and safety inference drawn from anecdotal human use.
Side-Effect Profiles: What the Trials and Pharmacology Studies Document
Tesamorelin (from Phase 3 RCT data): Injection-site reactions occurred in roughly 25 to 30 percent of subjects across the LIPO trials. Peripheral edema, arthralgia, and myalgia were the next most common events. Glucose metabolism changes were observed, consistent with GH-driven insulin resistance; the prescribing information notes monitoring is required in patients with or at risk for diabetes. Tesamorelin is contraindicated in active malignancy, pregnancy, and disrupted hypothalamic-pituitary axis (such as hypopituitarism) where the GHRH mechanism does not apply.
Hexarelin (from pharmacology literature, not RCT): Transient cortisol and prolactin elevations are documented in human studies, though the magnitude and clinical significance at research doses varies across subjects. Appetite stimulation is a recognized GHSR-1a effect (it is mechanistically identical to ghrelin signaling). Water retention and edema are plausible from GH elevation. No serious adverse event database exists because no large-scale human trial has been conducted.
Honest Head-to-Head Comparison Table
| Parameter | Hexarelin | Tesamorelin | Winner |
|---|---|---|---|
| Receptor target | GHSR-1a (ghrelin receptor) plus CD36 pathway | GHRH receptor (pituitary-selective) | Tesamorelin (cleaner target profile) |
| Human RCT data | None multi-month; acute pharmacology only | Two Phase 3 RCTs, N greater than 800 total | Tesamorelin (decisive) |
| Regulatory approval | None anywhere | FDA-approved (Egrifta/Egrifta SV) for HIV lipodystrophy | Tesamorelin (decisive) |
| Cortisol / prolactin stimulation | Yes, documented transiently | No meaningful effect | Tesamorelin (fewer off-target hormonal effects) |
| Desensitization risk | High with continuous use (GHSR-1a downregulation) | Lower; GHRH receptor less prone to rapid downregulation at therapeutic doses | Tesamorelin |
| Acute GH pulse magnitude | Often reported as higher per dose in comparative pharmacology | Moderate, more physiological pulsatility | Hexarelin (higher peak GH, but this is not always an advantage) |
| Appetite stimulation | Yes (ghrelin receptor mechanism) | No | Tesamorelin (for most use cases) |
| Cardioprotective signal | Preclinical data via CD36 pathway; mechanistically interesting | No direct cardiac pathway identified | Tie (hexarelin has signal, but evidence is preclinical only) |
| Pharmaceutical-grade product availability | No | Yes (Egrifta SV, 2 mg/day subcutaneous) | Tesamorelin (decisive) |
| WADA ban status | Banned (GHRP category) | Banned (GHRH analogue category) | Neither; both prohibited in sport |
Chemistry Behind the Rules: Why Storage and Stability Matter More Than You Think
Both hexarelin and tesamorelin are peptides, and all peptides share a core degradation vulnerability: the amide bonds in their backbone hydrolyze in aqueous solution, and the side chains of susceptible residues (methionine oxidizes, asparagine deamidates, tryptophan photo-degrades) are attacked by oxygen, light, and heat.
Hexarelin contains a D-2-methyltryptophan residue that was specifically engineered to resist some peptidase cleavage, but tryptophan indole rings remain highly sensitive to oxidation and UV exposure. A reconstituted hexarelin solution left at room temperature or exposed to light will accumulate oxidized byproducts that are neither pharmacologically equivalent to intact hexarelin nor fully characterized for safety. This is why cold storage and amber vials matter at the chemistry level, not as arbitrary rules.
Tesamorelin's trans-3-hexenoic acid modification at the N-terminus confers protease resistance primarily at that terminus, but the interior of the 44-amino-acid chain remains susceptible to the same aqueous degradation. The pharmaceutical Egrifta SV product undergoes formal accelerated stability testing under ICH guidelines. Research-grade tesamorelin has none of this. The practical rule: use reconstituted research peptides within 2 to 3 weeks at 2 to 8 degrees C in a bacteriostatic water vehicle, minimize freeze-thaw cycles, and protect from light. A degraded peptide does not smell or look different; it simply works less or unpredictably.
Operational and Label Literacy: How to Evaluate What You Are Buying
For tesamorelin (pharmaceutical Egrifta SV): The product ships as a lyophilized powder with a dedicated diluent. The prescribing information specifies exact reconstitution steps, storage conditions, and discard timing. If you are looking at a tesamorelin product that does not have an Egrifta or Egrifta SV label, it is not the pharmaceutical product and carries no guaranteed equivalence.
For any research-grade peptide (hexarelin or tesamorelin): Request a Certificate of Analysis (COA) that includes: HPLC purity (greater than 98% is a reasonable threshold; under 95% is concerning), mass spectrometry confirmation of molecular weight matching the target sequence, and ideally endotoxin testing (LAL assay) if any human use is anticipated. A COA that only shows a purity percentage without the analytical trace or the instrument details is not independently verifiable. Peptide content per vial claimed on the label should match the COA lot number.
Reconstitution math: A 2 mg vial of hexarelin reconstituted in 2 mL bacteriostatic water yields a 1 mg/mL (1000 mcg/mL) solution. A research dose often cited in the literature is in the range of 1 to 2 mcg per kg of body weight. For a 80 kg individual, that is 80 to 160 mcg per dose, which is 0.08 to 0.16 mL from a 1 mg/mL solution. Using an insulin syringe (100 units per mL), that corresponds to 8 to 16 units. These are not endorsements of any dose; they are arithmetic tools so you can verify claims made by suppliers or forums.
Desensitization and Cycling: What the Data Say
GHSR-1a, the hexarelin target, is a G-protein-coupled receptor. GPCRs desensitize through well-characterized mechanisms: phosphorylation by G-protein-coupled receptor kinases (GRKs) followed by beta-arrestin binding leads to receptor internalization. This is not a theoretical concern; it is a core pharmacological property of the receptor class. Published work with GHRP agonists including hexarelin demonstrates blunted GH responses with repeated dosing in both animal models and small human studies.
Tesamorelin's GHRH receptor also undergoes some regulatory feedback, but the Phase 3 trial data demonstrate sustained 15 to 18 percent VAT reductions over 26 weeks of daily 2 mg dosing, which would not be possible if complete receptor desensitization occurred at the timescale relevant for GHRPs. This is a practical differentiator: tesamorelin's approved clinical use involves continuous daily administration with sustained documented effect. Hexarelin continuous use lacks this support.
The widely cited recommendation to cycle hexarelin (for example, 8 weeks on, 4 weeks off) is mechanistically plausible given GHSR-1a biology, but the specific timing of any cycling protocol has no controlled trial basis. It is reasonable inference from receptor pharmacology, not clinical evidence.
FAQ
What is the core difference between hexarelin and tesamorelin?
Hexarelin is a synthetic GHRP that acts on the ghrelin receptor (GHSR-1a) to trigger GH pulses. Tesamorelin is a GHRH analogue that acts on the GHRH receptor to stimulate pulsatile GH release. Tesamorelin has a single FDA-approved indication (HIV-associated lipodystrophy); hexarelin has no approved human indication anywhere.
Which has stronger human clinical evidence, hexarelin or tesamorelin?
Tesamorelin has substantially stronger human evidence. Its approval rests on Phase 3 RCTs enrolling several hundred participants each. Hexarelin's human data consists of small pharmacokinetic and acute GH-secretion studies, with no multi-month RCT demonstrating a body-composition endpoint.
Does hexarelin raise cortisol and prolactin unlike tesamorelin?
Yes. Hexarelin activates both GHSR-1a and a distinct CD36-related receptor pathway, and human pharmacology studies have documented transient cortisol and prolactin elevations at standard research doses. Tesamorelin, acting through the GHRH receptor, does not produce clinically meaningful cortisol or prolactin stimulation at therapeutic doses.
Can tesamorelin reduce visceral fat without HIV?
Tesamorelin is only FDA-approved for HIV-associated lipodystrophy. Small investigational studies in non-HIV adults with abdominal obesity have shown visceral fat reduction, but none are Phase 3 RCTs, and tesamorelin is not approved or recommended for this off-label use. Evidence confidence for non-HIV visceral fat reduction is Low.
How quickly does desensitization occur with hexarelin?
Human and animal data show that continuous or high-frequency hexarelin administration leads to GHSR-1a downregulation and blunted GH responses within days to a few weeks. This tachyphylaxis is more pronounced than with GHRH analogues like tesamorelin, which preserve more physiological pulsatility.
What are the realistic side effects of tesamorelin?
In the Phase 3 trials, the most common adverse events included injection-site reactions (roughly 25 to 30 percent of subjects), peripheral edema, arthralgia, and myalgia. Glucose metabolism changes were observed, and tesamorelin is contraindicated in active malignancy.
How should hexarelin and tesamorelin be stored and reconstituted?
Both peptides are lyophilized powders that require refrigeration (2 to 8 degrees C) after reconstitution with bacteriostatic water. Hexarelin is less stable in solution and should be used within roughly 14 to 21 days when kept cold. Tesamorelin's approved product (Egrifta SV) has defined stability data on its label; research-grade tesamorelin does not.
Does hexarelin have cardiac effects separate from GH release?
Preclinical and small human studies have identified a direct cardiac GHS receptor pathway for hexarelin, with observed improvements in cardiac output in heart failure models. This is mechanistically interesting but not demonstrated in powered human trials. Confidence is Low for any clinical cardiac benefit.
Is hexarelin detectable on drug tests?
WADA bans all GH secretagogues including GHRPs such as hexarelin under the peptide hormone category. Specific urine and blood immunoassay detection methods for hexarelin and related GHRPs have been published by anti-doping laboratories. Athletes subject to testing should treat hexarelin as detectable.
Can hexarelin and tesamorelin be combined?
Combining a GHRP (hexarelin) with a GHRH analogue (tesamorelin) can produce additive or synergistic GH pulses because they act on different receptors. However, this combination has no human safety or efficacy trial data and amplifies risk of IGF-1 elevation, glucose dysregulation, and other GH-excess effects.
Which peptide is more appropriate for a supervised clinical context?
Tesamorelin is the only option with a defined regulatory approval, prescribing information, pharmacovigilance data, and pharmaceutical-grade product. Hexarelin exists only as a research compound in virtually all markets. For any supervised clinical use, tesamorelin is the evidence-supported choice by a wide margin.
Sources
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370.
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with 800 patients. Journal of Clinical Endocrinology and Metabolism. 2010;95(9):4291-4304.
- Egrifta SV (tesamorelin for injection) US Prescribing Information. Theratechnologies Inc. Available at FDA.gov. Accessed 2026.
- Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. European Journal of Endocrinology. 1997;136(5):445-460.
- Muccioli G, Tschop M, Papotti M, Deghenghi R, Heiman M, Ghigo E. Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. European Journal of Pharmacology. 2002;440(2-3):235-254.
- Broglio F, Arvat E, Benso A, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. Journal of Clinical Endocrinology and Metabolism. 2001;86(10):5083-5086.
- Torsello A, Bresciani E, Rossoni G, et al. Ghrelin plays a minor role in the physiological control of cardiac function in the rat. Endocrinology. 2003;144(5):1787-1792.
- Bodart V, Febbraio M, Bhatt D, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circulation Research. 2002;90(8):844-849.
- World Anti-Doping Agency (WADA). Prohibited List 2024. Available at wada-ama.org. Accessed 2026.
- Devesa J, Almenglo C, Devesa P. Multiple effects of growth hormone in the body: is it really the hormone for growth? Clinical Medicine Insights: Endocrinology and Diabetes. 2016;9:47-71.
- Koo GC, Huang C, Camacho R, et al. Immune enhancing effect of a growth hormone secretagogue. Journal of Immunology. 2001;166(6):4195-4201.